Found 582 results
Author [ Keyword(Desc)] Title Type Year
Filters: Author is Williams, David E  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
HCT116 Cells
Wang R, Löhr CV, Fischer K, W Dashwood M, Greenwood JA, Ho E, Williams DE, Ashktorab H, Dashwood MR, Dashwood RH.  2013.  Epigenetic inactivation of endothelin-2 and endothelin-3 in colon cancer.. Int J Cancer. 132(5):1004-12.
Heating
Krueger SK, Martin SR, Yueh M-F, Pereira CB, Williams DE.  2002.  Identification of active flavin-containing monooxygenase isoform 2 in human lung and characterization of expressed protein.. Drug Metab Dispos. 30(1):34-41.
Histone Deacetylase 2
Beaver LM, Yu T-W, Sokolowski EI, Williams DE, Dashwood RH, Ho E.  2012.  3,3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells.. Toxicol Appl Pharmacol. 263(3):345-51.
Histone Deacetylase 6
Watson GW, Wickramasekara S, Fang Y, Maier CS, Williams DE, Dashwood RH, Perez VI, Ho E.  2016.  HDAC6 activity is not required for basal autophagic flux in metastatic prostate cancer cells.. Exp Biol Med (Maywood). 241(11):1177-85.
Histone Deacetylase Inhibitors
Rajendran P, Kidane AI, Yu T-W, Dashwood W-M, Bisson WH, Löhr CV, Ho E, Williams DE, Dashwood RH.  2013.  HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates.. Epigenetics. 8(6):612-23.
Beaver LM, Yu T-W, Sokolowski EI, Williams DE, Dashwood RH, Ho E.  2012.  3,3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells.. Toxicol Appl Pharmacol. 263(3):345-51.
Rajendran P, Williams DE, Ho E, Dashwood RH.  2011.  Metabolism as a key to histone deacetylase inhibition.. Crit Rev Biochem Mol Biol. 46(3):181-99.
Histone Deacetylases
Rajendran P, Williams DE, Ho E, Dashwood RH.  2011.  Metabolism as a key to histone deacetylase inhibition.. Crit Rev Biochem Mol Biol. 46(3):181-99.
Beaver LM, Yu T-W, Sokolowski EI, Williams DE, Dashwood RH, Ho E.  2012.  3,3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells.. Toxicol Appl Pharmacol. 263(3):345-51.
Rajendran P, Kidane AI, Yu T-W, Dashwood W-M, Bisson WH, Löhr CV, Ho E, Williams DE, Dashwood RH.  2013.  HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates.. Epigenetics. 8(6):612-23.
Watson GW, Wickramasekara S, Fang Y, Maier CS, Williams DE, Dashwood RH, Perez VI, Ho E.  2016.  HDAC6 activity is not required for basal autophagic flux in metastatic prostate cancer cells.. Exp Biol Med (Maywood). 241(11):1177-85.
Histones
Ho E, Beaver LM, Williams DE, Dashwood RH.  2011.  Dietary factors and epigenetic regulation for prostate cancer prevention.. Adv Nutr. 2(6):497-510.
Hot Temperature
Krueger SK, Henderson MC, Siddens LK, VanDyke JE, Benninghoff AD, P Karplus A, Furnes B, Schlenk D, Williams DE.  2009.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.. Drug Metab Dispos. 37(8):1785-91.
HT29 Cells
Wang R, Löhr CV, Fischer K, W Dashwood M, Greenwood JA, Ho E, Williams DE, Ashktorab H, Dashwood MR, Dashwood RH.  2013.  Epigenetic inactivation of endothelin-2 and endothelin-3 in colon cancer.. Int J Cancer. 132(5):1004-12.
Humans
Rajendran P, Williams DE, Ho E, Dashwood RH.  2011.  Metabolism as a key to histone deacetylase inhibition.. Crit Rev Biochem Mol Biol. 46(3):181-99.
Krueger SK, VanDyke JE, Williams DE, Hines RN.  2006.  The role of flavin-containing monooxygenase (FMO) in the metabolism of tamoxifen and other tertiary amines.. Drug Metab Rev. 38(1-2):139-47.
Bailey GS, Reddy AP, Pereira CB, Harttig U, Baird W, Spitsbergen JM, Hendricks JD, Orner GA, Williams DE, Swenberg JA.  2009.  Nonlinear cancer response at ultralow dose: a 40800-animal ED(001) tumor and biomarker study.. Chem Res Toxicol. 22(7):1264-76.
Krueger SK, Henderson MC, Siddens LK, VanDyke JE, Benninghoff AD, P Karplus A, Furnes B, Schlenk D, Williams DE.  2009.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.. Drug Metab Dispos. 37(8):1785-91.
Rajendran P, Kidane AI, Yu T-W, Dashwood W-M, Bisson WH, Löhr CV, Ho E, Williams DE, Dashwood RH.  2013.  HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates.. Epigenetics. 8(6):612-23.
Madeen EP, Löhr CV, You H, Siddens LK, Krueger SK, Dashwood RH, Gonzalez FJ, Baird WM, Ho E, Bramer L et al..  2017.  Dibenzo[def,p]chrysene transplacental carcinogenesis in wild-type, Cyp1b1 knockout, and CYP1B1 humanized mice.. Mol Carcinog. 56(1):163-171.
Wang R, Chen Y-S, Dashwood W-M, Li Q, Löhr CV, Fischer K, Ho E, Williams DE, Dashwood RH.  2017.  Divergent roles of p120-catenin isoforms linked to altered cell viability, proliferation, and invasiveness in carcinogen-induced rat skin tumors.. Mol Carcinog. 56(7):1733-1742.
Watson GW, Wickramasekara S, Fang Y, Maier CS, Williams DE, Dashwood RH, Perez VI, Ho E.  2016.  HDAC6 activity is not required for basal autophagic flux in metastatic prostate cancer cells.. Exp Biol Med (Maywood). 241(11):1177-85.
Wang R, Löhr CV, Fischer K, W Dashwood M, Greenwood JA, Ho E, Williams DE, Ashktorab H, Dashwood MR, Dashwood RH.  2013.  Epigenetic inactivation of endothelin-2 and endothelin-3 in colon cancer.. Int J Cancer. 132(5):1004-12.
Leibelt DA, Hedstrom OR, Fischer KA, Pereira CB, Williams DE.  2003.  Evaluation of chronic dietary exposure to indole-3-carbinol and absorption-enhanced 3,3'-diindolylmethane in sprague-dawley rats.. Toxicol Sci. 74(1):10-21.
Beaver LM, Yu T-W, Sokolowski EI, Williams DE, Dashwood RH, Ho E.  2012.  3,3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells.. Toxicol Appl Pharmacol. 263(3):345-51.

Pages